AARP reveals Medicare drug negotiation could save $200 billion

In the United States, a recent report from AARP highlighted a proposal aimed at expanding Medicare's prescription drug negotiation program. This proposal, if approved by Congress, could potentially save the federal government nearly $200 billion while also lowering costs for millions of seniors. The report specifically analyzed Medicare spending on ten high-cost brand-name drugs, suggesting that if manufacturers were required to match the lowest prices paid for these medications in comparable high-income countries, significant savings could be achieved. The concept is often referred to as 'most-favored-nation' pricing, which aims to ensure that American consumers are not paying more than those in other wealthy nations.

The findings of the report are particularly relevant given the ongoing concerns regarding prescription drug affordability among older Americans enrolled in Medicare. The Inflation Reduction Act had previously granted Medicare the authority to negotiate prices for certain high-cost medications, but AARP believes that the program could be further strengthened to generate additional savings and help stabilize future Medicare Part D premiums. The analysis indicated that the ten drugs in question accounted for nearly $50 billion in Medicare spending in 2025 and were utilized by over three million seniors.

Researchers found that applying a most-favored-nation pricing model could dramatically reduce projected Medicare spending on these drugs from $273 billion to $76 billion between 2029 and 2033. This represents a potential savings of nearly $200 billion, which could have a significant impact on the financial burden faced by seniors who rely on these medications. AARP's Executive Vice President, Nancy LeaMond, emphasized the need for action, stating that big drug companies have historically charged Americans the highest prescription drug prices in the world, forcing many older adults to skip or ration necessary medications due to cost.

Despite the potential benefits of this proposal, it is important to note that current laws limit the number of drugs eligible for negotiation. AARP's analysis revealed that only one of the ten high-cost drugs examined would be eligible for Medicare drug price negotiation in the upcoming year, even though these drugs collectively account for billions in Medicare spending. The organization is urging federal officials to broaden the program to include more drugs while ensuring that Part D coverage remains affordable for beneficiaries. The transition to broader negotiations could lead to lower pharmacy bills for seniors, but achieving this would require Congress to expand or maintain Medicare's authority in the face of significant opposition from the pharmaceutical industry.